Navigation Links
Shire Reaches Agreement in Principle With U.S. Government
Date:2/1/2013

PHILADELPHIA, February 1, 2013 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG), today announced that it has reached an agreement in principle to resolve the previously disclosed civil investigation into Shire's U.S. sales and marketing practices relating to ADDERALL XR®, VYVANSE® and DAYTRANA®[1].  

The investigation was led by the U.S. Attorney's Office for the Eastern District of Pennsylvania, and Shire disclosed the investigation in 2009.  The agreement also addresses sales and marketing practices relating to LIALDA® and PENTASA® pursuant to a subsequent voluntary disclosure made by Shire.  

Shire cooperated with the U.S. Government throughout the process that led to this agreement in principle.  Shire has recorded a $57.5M charge in the fourth quarter of 2012, comprised of the agreement in principle amount, interest and costs.  

The agreement in principle is subject to change until this matter is finally resolved.  Discussions between Shire and the U.S. Government are ongoing to establish a final resolution to the investigation.

Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients' needs, we develop and provide healthcare in the areas of:

  • Behavioral Health and Gastro Intestinal conditions
  • Rare Diseases
  • Regenerative Medicine

as well as other symptomatic conditions treated by specialist physicians.

--------------------------------------------------

1. DAYTRANA® is a trademark of Noven Pharmaceutical Inc.

We aspire to imagine and lead the future of healthcare, creating value for patients, physicians, policymakers, payors and our shareholders.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, as well as the ability to secure new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

For further information please contact:

Investor Relations Eric Rojas erojas@shire.com +1-781-482-0999 Sarah Elton-Farr seltonfarr@shire.com +44(0)1256-894157 Media Jessica Mann (Corporate) jmann@shire.com +44(0)1256-894-280


'/>"/>
SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
2. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
3. Shire Changes its NASDAQ Ticker Symbol to SHPG
4. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
5. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
6. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
7. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
8. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
9. Mold from Sandy Remains a Problem in Rockaways; My Cleaning Products Reaches Out to Help with Its Green Mold Removal Spray
10. K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
11. Cold Adds Up to Sandy Victims' Mold Problems; Optimal Chemical Reaches Out to Help by Advising the Use of Molderizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... Jan. 12, 2017   Protein Sciences Corporation ... of Flublok Influenza Vaccine ®, announced today ... had good safety results and induced strong neutralizing ... The product is expected to advance into human ... addition, the Institute of Technology in Immunobiologicals of ...
(Date:1/12/2017)... (PRWEB) , ... January 12, ... ... market’s rapid adoption of Limfinity® Cloud, RURO has enhanced the platform to ... user groups, federated login, rapid data searching, and more. In addition to ...
(Date:1/11/2017)... ... January 11, 2017 , ... As ... in Peru studying the pathogens that cause malaria and tuberculosis. Seeing firsthand the ... of discovery. , Now, as an assistant professor of biology and biotechnology at ...
(Date:1/11/2017)... Linda, Ca (PRWEB) , ... January 11, 2017 ... ... the U.S. each year and costing healthcare systems more than $23.7 billion, ... while controlling costs. , Among the most common sepsis-causing pathogens are bacteria ...
Breaking Biology Technology:
(Date:1/11/2017)... Jan. 11, 2017  Michael Johnson, co-founder of Visikol Inc. a ... Inc., has been named to the elite "Forbes 30 Under 30" ... of 600 people in 20 fields nationwide to be recognized as ... 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers University. ...
(Date:1/6/2017)... 2017  Delta ID Inc., a leader in consumer-grade ... automotive at CES® 2017. Delta ID has collaborated with ... the use of iris scanning as a secure, reliable ... in a car, and as a way to elevate ... Delta ID and Gentex will demonstrate (booth #7326 ...
(Date:1/3/2017)... LAS VEGAS , Jan. 3, 2017 ... announced the introduction of Onitor Track, an innovative biometric ... and men, showcasing this month at the 2017 Consumer ... . In the U.S., the World ... affect more than two-thirds of adults who are overweight ...
Breaking Biology News(10 mins):